公开(公告)号：WO2017004678A1

公开(公告)日：2017-01-12

申请号：PCT/AU2016/050594

申请日：2016-07-07

Applicant: THE UNIVERSITY OF SYDNEY ,  WESTERN SYDNEY LOCAL HEALTH DISTRICT

Inventor： GOTTLIEB, David ,  CLANCY, Leighton

IPC: A61K39/00 ,  A61K35/17

CPC classification number: A61K35/17 ,  A61K39/0002 ,  C12N2710/10334 ,  C12N2760/16034 ,  Y02A50/467

Abstract: The present invention provides a method to manufacture panfungal T-cell products with specificity against a range of clinical fungal pathogens by use of the blood and stem cells of healthy donors as the starting material. Specifically, the combination of T cells stimulated by lysates of Aspergillus terreus and Candida krusei provides a broadly cross-reactive T cell population. In another embodiment, lysate of Rhizopus oryzae are also used.

Abstract translation: 本发明提供了通过使用健康供体的血液和干细胞作为起始材料来制造对一系列临床真菌病原体具有特异性的全真菌T细胞产物的方法。 具体来说，由Aspergillus terreus和Candida krusei的裂解物刺激的T细胞的组合提供了广泛的交叉反应性T细胞群体。 在另一个实施方案中，还使用了米曲霉（Rhizopus oryzae）的裂解物。

公开(公告)号：WO2016081355A1

公开(公告)日：2016-05-26

申请号：PCT/US2015/060850

申请日：2015-11-16

Applicant: BIOGEN MA INC.

Inventor： NOVAS, Mark ,  ZHANG, Rui, (Ray)

IPC: A61K31/225 ,  A61P25/02

CPC classification number: A61K31/225 ,  A61K9/0053 ,  A61K9/28 ,  A61K9/4808 ,  A61K9/4825 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  A61K47/542 ,  A61K47/545 ,  G01N33/492 ,  G09B19/00 ,  Y02A50/467

Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.

Abstract translation: 本文提供了用富马酸盐治疗多发性硬化的方法，其中富马酸盐是富马酸二烷基酯，富马酸单烷基酯，富马酸二烷基酯和富马酸单烷基酯的组合，富马酸单烷基酯的前药，任何前述的氘代形式， 或上述任一项的药学上可接受的盐，包合物，溶剂化物，互变异构体或立体异构体，或任何上述物质的组合。 本文提供的方法通过告知和监测进行多发性脑白质脑病的治疗的患者和/或通过监测淋巴细胞计数来改善治疗的安全性。

公开(公告)号：WO2015154820A1

公开(公告)日：2015-10-15

申请号：PCT/EP2014/057398

申请日：2014-04-11

Applicant: PANOPTES PHARMA GMBH

Inventor： STROBL, Stefan

IPC: A61K31/196 ,  A61K31/341 ,  A61K31/381 ,  A61K31/44 ,  A61P31/12

CPC classification number: A61K31/381 ,  A61K31/196 ,  A61K31/341 ,  A61K31/44 ,  Y02A50/467

Abstract: The present invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, for use in the treatment of medical conditions which are caused by an adeno virus, HHV (human herpesvirus), VZV (varicella zoster virus), HSV (herpes simplex virus), EBV (Epstein-Barr virus), vaccinia virus, or BK virus.

Abstract translation: 本发明涉及通式（I）化合物及其盐和生理功能衍生物，用于治疗由腺病毒，HHV（人疱疹病毒），VZV（水痘带状疱疹病毒）， HSV（单纯疱疹病毒），EBV（爱泼斯坦 - 巴尔病毒），痘苗病毒或BK病毒。

公开(公告)号：WO2015004533A2

公开(公告)日：2015-01-15

申请号：PCT/IB2014/002238

申请日：2014-06-20

Applicant: ZENITH EPIGENETICS CORP.

Inventor： LIU, Shuang ,  QUINN, John, Frederick ,  DUFFY, Bryan, Cordell ,  WANG, Ruifang ,  JIANG, May, Xiaowu ,  MARTIN, Gregory, Scott ,  ZHAO, He ,  ELLIS, Michael ,  WAGNER, Gregory, Steven ,  YOUNG, Peter, Ronald

CPC classification number: A61K31/4184 ,  A61K31/422 ,  A61K31/423 ,  A61K31/426 ,  A61K31/427 ,  A61K31/428 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/538 ,  A61K45/06 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  Y02A50/467

Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.

Abstract translation: 本发明涉及取代的双环化合物，其可用于通过结合溴结构域来抑制BET蛋白功能，包含这些化合物的药物组合物，以及这些化合物和组合物在治疗中的用途。

公开(公告)号：WO2014186469A2

公开(公告)日：2014-11-20

申请号：PCT/US2014/038005

申请日：2014-05-14

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Inventor： COOPER, Laurence, J.N. ,  WANG-JOHANNING, Feng ,  TORIKAI, Horoki ,  HULS, Helen ,  HURTON, Lenka ,  KRISHNAMURTHY, Janani ,  OLIVARES, Simon ,  ZHANG, Ling

CPC classification number: A61K35/17 ,  C07K14/5443 ,  C07K14/7051 ,  Y02A50/411 ,  Y02A50/467

Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease ( e.g., cancer) treatment.

Abstract translation: 本发明涉及使用包含嵌合抗原受体（CAR）的修饰T细胞的免疫治疗方法和组合物。 在特定方面，CAR表达的T细胞使用电穿孔与基于转座子的整合系统一起产生，以产生需要最小离体扩增或可以直接向患者施用疾病的CAR表达细胞群体（例如 ，癌症）治疗。

公开(公告)号：WO2014143643A1

公开(公告)日：2014-09-18

申请号：PCT/US2014/027005

申请日：2014-03-14

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION

Inventor： HOSTETLER, Karl Y. ,  BEADLE, James R. ,  VALIAEVA, Nadejda

IPC: C07F9/40 ,  C07F9/6512 ,  C07F9/6524 ,  A61K31/675 ,  A61K31/662 ,  A61K31/522 ,  A61K31/513 ,  A61P31/12 ,  A61P31/18 ,  A61P31/22 ,  A61P35/00

CPC classification number: A61K31/685 ,  A61K9/0014 ,  A61K9/0031 ,  A61K9/0034 ,  A61K31/675 ,  C07F9/65121 ,  C07F9/65583 ,  C07F9/6561 ,  C07F9/65616 ,  Y02A50/467

Abstract: The present disclosure relates, inter alia , to compositions and methods for treating viral diseases and cancer. There are disclosed lipophilic antiviral and anticancer acyclic nucleoside phosphonate diesters, preparation thereof, and methods of using the compounds to treat viral diseases and cancer.

Abstract translation: 本公开尤其涉及用于治疗病毒性疾病和癌症的组合物和方法。 公开了亲脂性抗病毒和抗癌非环型核苷膦酸二酯，其制备方法和使用该化合物治疗病毒性疾病和癌症的方法。

公开(公告)号：WO2014116723A1

公开(公告)日：2014-07-31

申请号：PCT/US2014/012577

申请日：2014-01-22

Applicant: THE CHARLES STARK DRAPER LABORATORY, INC. ,  COMOLLI, James ,  TREVEJO, Jose ,  SASISSEKHARAN, Ram ,  SHRIVER, Zachary ,  VISWANATHAN, Karthik ,  FYGENSON, Deborah ,  FINBERG, Robert ,  WANG, Jennifer

Inventor： COMOLLI, James ,  TREVEJO, Jose ,  SASISSEKHARAN, Ram ,  SHRIVER, Zachary ,  VISWANATHAN, Karthik ,  FYGENSON, Deborah ,  FINBERG, Robert ,  WANG, Jennifer

IPC: A61K9/127 ,  A61K47/48 ,  A61K31/702 ,  A61P31/16 ,  A61P31/04 ,  A61P39/00

CPC classification number: A61K38/162 ,  A61K31/7012 ,  A61K47/6911 ,  Y02A50/467

Abstract: This disclosure provides compositions, kits, and methods useful for treating or preventing viral and bacterial infection and reducing or preventing the effects of toxins. The methods comprise administering to a subject an effective amount of a liposomal composition.

Abstract translation: 本公开提供了用于治疗或预防病毒和细菌感染以及减少或预防毒素作用的组合物，试剂盒和方法。 所述方法包括向受试者施用有效量的脂质体组合物。

公开(公告)号：WO2014049447A2

公开(公告)日：2014-04-03

申请号：PCT/IB2013/002848

申请日：2013-09-17

Applicant: BIOPEP SOLUTIONS, INC.

Inventor： MERZOUK, Ahmed ,  GHAWI, Abbas, Mohammad ,  ABDUALKADER, Abdualrahman, M. ,  ALAAMA, Mohamed

IPC: A61K35/62

CPC classification number: A61K35/62 ,  A01K67/033 ,  A01N63/00 ,  A61K9/0014 ,  A61K31/282 ,  A61K31/4745 ,  A61K31/555 ,  A61K38/21 ,  A61K45/06 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/393 ,  Y02A50/40 ,  Y02A50/401 ,  Y02A50/402 ,  Y02A50/406 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/415 ,  Y02A50/419 ,  Y02A50/422 ,  Y02A50/423 ,  Y02A50/463 ,  Y02A50/465 ,  Y02A50/467 ,  Y02A50/469 ,  Y02A50/47 ,  Y02A50/471 ,  Y02A50/473 ,  Y02A50/479 ,  Y02A50/481 ,  Y02A50/483 ,  Y02A50/491 ,  A61K2300/00

Abstract: Methods are provided for isolating and using a whole-saliva leech extract. The methods can include feeding a phagostimulatory agent to a leech; inducing a regurgitation in the leech, the inducing including placing the leech in an environment having a temperature of less than about 0°C; and, collecting an unrefined, whole saliva in the regurgitation of the cooled leech. The methods can include revitalizing the leech by warming it at a temperature ranging from about 5°C to about 40°C. Stable, lyophilized, whole-saliva extracts of a leech are also provided, the extract having a stable activity when stored for use at a temperature below about -20°C, the extract maintaining at least 70% of the activity for at least 6 months. The extracts can be used to treat solid tumors, treat liquid tumors, treat diabetes, treat a viral disease, treat a parasitic disease, treat an antibacterial disease, or serve as an anti-oxidant.

Abstract translation: 提供了分离和使用全唾液水蛭提取物的方法。 该方法可以包括将吞噬刺激剂喂给水蛭; 诱导水蛭反流，诱导包括将水蛭放置在温度低于约0℃的环境中; 并且在冷却的水蛭的反流中收集未精制的全唾液。 所述方法可以包括通过在约5℃至约40℃的温度下加热它来使水蛭复活。 还提供了水蛭的稳定的，冻干的全唾液提取物，当在低于约-20℃的温度下储存时，提取物具有稳定的活性，提取物保持至少70％的活性至少6个月 。 该提取物可用于治疗实体瘤，治疗液体肿瘤，治疗糖尿病，治疗病毒性疾病，治疗寄生虫病，治疗抗菌疾病或用作抗氧化剂。

公开(公告)号：WO2014014814A1

公开(公告)日：2014-01-23

申请号：PCT/US2013/050479

申请日：2013-07-15

Applicant: BROWN UNIVERSITY

Inventor： ATWOOD, Walter ,  NELSON, Christian ,  SELLO, Jason, K: ,  CARNEY, Daniel, William

IPC: A61K31/506 ,  A61K31/505 ,  A61K31/495 ,  A61P31/18 ,  A61P31/00

CPC classification number: C07D409/04 ,  A61K31/517 ,  C07D403/04 ,  C07D405/04 ,  Y02A50/467 ,  Y02A50/471 ,  Y02A50/473

Abstract: Provided herein are compounds of Formula (I) or (II): (I) (II) harmaceutically acceptable salts, tautomers, prodrugs, and stereoisomers thereof, and pharmaceutical compositions thereof, wherein X, R N , R 1 , R 3 , R 4 , p, and m are as defined herein. Such compounds and compositions have been found useful in the treatment or prevention of viral infections, e.g ., polyomaviral infections, and are further envisioned useful in treatment or prevention of other pathogenic conditions associated with endosomal trafficking. Methods of treating or preventing an infection by a pathogen secreting an AB 5 toxin is also contemplated.

Abstract translation: 本文提供式（I）或（II）的化合物：（I）（II）其药学上可接受的盐，互变异构体，前药和立体异构体及其药物组合物，其中X，RN，R1，R3，R4，p， 和m如本文所定义。 已经发现这样的化合物和组合物可用于治疗或预防病毒感染，例如多聚病毒感染，并且进一步设想可用于治疗或预防与内体运输相关的其它病原性病症。 还考虑了治疗或预防分泌AB5毒素的病原体的感染的方法。

公开(公告)号：WO2012031045A2

公开(公告)日：2012-03-08

申请号：PCT/US2011/050099

申请日：2011-08-31

Applicant: CHIMERIX, INC. ,  WARE, Roy, W. ,  ALMOND, Merrick, R. ,  LAMPERT, Bernhard, M.

Inventor： WARE, Roy, W. ,  ALMOND, Merrick, R. ,  LAMPERT, Bernhard, M.

IPC: C07F9/38 ,  C07F9/40 ,  A61K31/675 ,  A61K47/48 ,  A61P31/12

CPC classification number: C07F9/4021 ,  A61K31/675 ,  C07F9/3808 ,  C07F9/4006 ,  C07F9/65121 ,  C07F9/657181 ,  Y02A50/467 ,  Y02P20/55

Abstract: The disclosure describes methods of synthesis of phosphonate ester derivatives. Preferred methods according to the disclosure allow for large-scale preparation of phosphonate ester compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of phosphonate ester derivatives without the use of chromatographic purification methods and in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of phosphonate ester derivatives.

Abstract translation: 本公开描述了合成膦酸酯衍生物的方法。 根据本公开的优选方法允许大规模制备具有高纯度的膦酸酯化合物。 在一些实施方案中，根据本公开内容的优选方法还允许制备膦酸酯衍生物而不使用色谱纯化方法并且以比先前使用的制备此类化合物的方法更好的收率。 还公开了膦酸酯衍生物的形态形式。